Janus kinase inhibitor - Wikipedia
Janus kinase inhibitor ... A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family …
What are JAK inhibitors and how do they work? - Drugs.com
Jul 15, 2025 · Janus kinase (JAK) inhibitors are a group of medicines that help block immune system signals in the body that can lead to swelling (inflammation) and pain in conditions like rheumatoid …
JAK Inhibitors: Uses, Types, Side Effects, and More
Aug 23, 2025 · In this article, learn about the dosage, uses, and ongoing research underway for JAK inhibitors available in the United States, as well as common side effects, contraindications, and …
JAK inhibitors: an evidence-based choice of the most appropriate ...
Recently, Janus kinase inhibitors (JAKi) have been developed to block the effect of proinflammatory cytokines in IMIDs.
List of the 9 Leading JAK Inhibitor Drugs - GoodRx
Aug 13, 2024 · Janus kinase (JAK) inhibitors are a group of medications with many uses. Rinvoq (upadacitinib), Xeljanz (tofacitinib), and Cibinqo (abrocitinib) are options for eczema and other …
JAK Inhibitors 101 - The Rheumatologist
Jul 28, 2025 · The JAK-signal transducer and activator of transcription (STAT) pathway is central to immune dysregulation in many autoimmune diseases due to its role in transducing signals from an …
JAK inhibitors: What your dermatologist wants you to know
Thanks to this breakthrough research, JAK inhibitors are FDA approved to treat conditions that include eczema, psoriasis, and vitiligo. What makes this medication unique is the way it works. A JAK …
Understanding the Mechanism of Action in JAK Inhibitors
Jun 2, 2024 · Jason Hawkes, MD, MS, medical dermatologist in Sacramento, California presented an in-depth overview on the mechanism of action (MOA) of Janus Kinase (JAK) inhibitors, a class of small …
FDA-Approved JAK Inhibitors in Myelofibrosis: Mechanisms, …
Jan 12, 2026 · Four JAK inhibitors—ruxolitinib, fedratinib, pacritinib, and momelotinib—are FDA-approved for the treatment of myelofibrosis, each with nuanced differences in clinical indications. …
JAK Inhibitors Improve Immune Checkpoint Inhibitors - NCI
Aug 8, 2024 · JAK proteins—the targets of JAK inhibitors—are like puppet masters, pulling the strings that control numerous cellular functions, including inflammation and immune cell activity.